PTEN Deficiency and Treatment Optimization in mHSPC

Gordon A. Brown, DO, FACOS, gives an overview of PTEN biology, distinctions between PTEN loss and deficiency, and the clinical importance of PI3K/AKT pathway activation in prostate cancer progression.

In this video, Gordon A. Brown, DO, FACOS, discusses PTEN deficiency as a prognostic marker and its implications for treatment selection, monitoring, and risk stratification in mHSPC.

Gordon A. Brown, DO, FACOS, reviews rPFS outcomes demonstrating clinical benefit with capivasertib plus abiraterone in PTEN-deficient mHSPC.

In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response.

Gordon A. Brown, DO, FACOS, summarizes overall survival trends, safety findings, and clinical considerations for managing adverse events with dual pathway inhibition.

In this video, Gordon A. Brown, DO, FACOS, offers perspective on integrating PTEN testing and AKT inhibition into evolving biomarker-driven treatment strategies for mHSPC.